WCG
FBIO icon

Weaver Consulting Group’s Fortress Biotech FBIO Stock Holding History

Weaver Consulting Group’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,367
Closed -$31.7K – 307
2026
Q2 		$31.7K Sell
10,367
-1,000
-9% -$2.58K 0.01% 297
2026
Q1 		$31.7K Sell
11,367
-8,165
-42% -$27.7K 0.01% 275
2025
Q4 		$71.5K Sell
19,532
-1,080
-5% -$3.08K 0.02% 268
2025
Q3 		$76.2K Sell
20,612
-24,305
-54% -$61.5K 0.02% 263
2025
Q2 		$83.5K Sell
44,917
-1,500
-3% -$2.6K 0.02% 243
2025
Q1 		$72.4K Buy
46,417
+23,419
+102% +$41.3K 0.02% 220
2024
Q4 		$46.6K Buy
22,998
+5,700
+33% +$10.3K 0.01% 217
2024
Q3 		$25K Buy
17,298
+5,895
+52% +$11.2K 0.01% 222
2024
Q2 		$19.5K Buy
+11,403
New +$20.7K 0.01% 203

Weaver Consulting Group's FBIO Position: Q3 2026 in Review

Weaver Consulting Group sold out of Fortress Biotech (FBIO) in Q3 2026, closing a stake of 10,367 shares — an estimated $31.7K sold.

Weaver Consulting Group first reported a position in FBIO in Q2 2024 and held it in 9 quarters. The position peaked at $83.5K in Q2 2025. 0 funds tracked by Wall St. Rank hold FBIO as of Q3 2026.

  • Weaver Consulting Group reported no remaining Fortress Biotech position as of Q3 2026 after selling out during the quarter.
  • Weaver Consulting Group sold 10,367 Fortress Biotech shares in Q3 2026, an estimated $31.7K.
  • Weaver Consulting Group first reported a position in Fortress Biotech in Q2 2024 and held it in 9 quarters.
  • Weaver Consulting Group's Fortress Biotech position peaked at $83.5K in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2026.

Based on Weaver Consulting Group's 13F filing for Q3 2026, filed 7 Oct 2026.